Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT

TY - JOUR

T1 - Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT

AU - Vercellino, Laetitia

AU - Groheux, David

AU - Thoury, Anne

AU - Delord, Marc

AU - Schlageter, Marie-Hélène

AU - Delpech, Yann

AU - Barré, Emmanuelle

AU - Baruch-Hennequin, Valérie

AU - Tylski, Perrine

AU - Homyrda, Laurence

AU - Walker, Francine

AU - Barranger, Emmanuel

AU - Hindié, Elif

PY - 2012/11

Y1 - 2012/11

N2 - PURPOSE: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG.PATIENTS AND METHODS: We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. (18)F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes.RESULTS: All tumors were detected by (18)F-FDG PET. (18)F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between (18)F-FETNIM and (18)F-FDG uptake. High (18)F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 μg/L (median, 102.5 μg/L). Patients with OPN greater than 144 μg/L had reduced progression-free survival compared with those with OPN less than 144 μg/L (log-rank = 0.03). We found no significant correlation between (18)F-FETNIM uptake and OPN blood levels.CONCLUSIONS: Our preliminary results showed that a high uptake of (18)F-FETNIM was associated with a worse progression-free and overall survival.

AB - PURPOSE: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG.PATIENTS AND METHODS: We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. (18)F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes.RESULTS: All tumors were detected by (18)F-FDG PET. (18)F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between (18)F-FETNIM and (18)F-FDG uptake. High (18)F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 μg/L (median, 102.5 μg/L). Patients with OPN greater than 144 μg/L had reduced progression-free survival compared with those with OPN less than 144 μg/L (log-rank = 0.03). We found no significant correlation between (18)F-FETNIM uptake and OPN blood levels.CONCLUSIONS: Our preliminary results showed that a high uptake of (18)F-FETNIM was associated with a worse progression-free and overall survival.

KW - Adult

KW - Aged

KW - Disease-Free Survival

KW - Female

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Hypoxia/diagnostic imaging

KW - Imaging, Three-Dimensional

KW - Middle Aged

KW - Multimodal Imaging

KW - Nitroimidazoles

KW - Positron-Emission Tomography

KW - Tomography, X-Ray Computed

KW - Uterine Cervical Neoplasms/diagnostic imaging

U2 - 10.1097/RLU.0b013e3182638e7e

DO - 10.1097/RLU.0b013e3182638e7e

M3 - Article

C2 - 22996235

SN - 0363-9762

VL - 37

SP - 1065

EP - 1068

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 11

ER -